|
|
 |
|
News/Event Item
UMB's Shigella Vaccine Licensed to PATH
Nov. 24, 2008
The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries.
Each year, an estimated 1.1 million people die from Shigella infections, a major cause of diarrhea and dysentery, reports the World Health Organization (WHO). More than 60 percent of the deaths reported were children less than five years of age.
"The live oral Shigella vaccine created at the School of Medicine's Center for Vaccine Development is the culmination of more than a decade of dedication to serving the chronically underserved, and this partnership is critical to achieving a better world for those populations," says Libby Hart-Wells, PhD, an executive director at UMB's Office of Research and Development.
© 2007 University of Maryland, Baltimore
For full article, visit:
http://www.oea.umaryland.edu/communications/news/?ViewStatus=FullArticle&articleDetail=4935
category: Member Organization News : General Health News
contributed by Liza Nanni on 25 November 2008
Global :
recall this item.
|
|
Share
